Affitech A/S
Major shareholder transaction: Notification pursuant to Section 28a of the Danish Securities Trading Act

Affitech A/S 

05.09.2012 15:58

Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Release no. 26/2012

Copenhagen and Oslo, 2012-09-05 15:58 CEST (GLOBE NEWSWIRE) -- 
In accordance with Section 28a of the Danish Securities Trading Act, this is to
notify, on behalf of Alexander Shuster, Chairman of the Board of Directors of
Affitech A/S, of the following transactions: 





Name                            Trans Nova Investments Limited                  
--------------------------------------------------------------------------------
Reason for reporting            Related party to Alexander Shuster, Chairman of 
                                 the Board of Affitech A/S                      
--------------------------------------------------------------------------------
Issuer and ISIN                 Affitech A/S/DK0015966592                       
--------------------------------------------------------------------------------
Type of transaction             Purchase of shares                              
--------------------------------------------------------------------------------
Date of transaction             4th September, 2012                             
--------------------------------------------------------------------------------
Relevant market                 NASDAQ OMX COPENHAGEN A/S                       
--------------------------------------------------------------------------------
Number of traded securities     193,412 shares. Market value DKK 38,663         
 and market value                                                               
--------------------------------------------------------------------------------





About Affitech

Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS(TM) (Cell Based Antibody Selection) is
Affitech's premier discovery engine for the isolation of lead antibodies to
cell surface molecules in situ. Several of the Company's proprietary product
candidates were generated by CBAS(TM). Further information is available at
www.affitech.com. 




         Contact
         
         Randi Krogsgaard, Director IR & Communications
         
         Tel # +45 2320 1001, e-mail: ir@affitech.com
News Source: NASDAQ OMX



05.09.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Affitech A/S
              
               
              Denmark
Phone:        
Fax:          
E-mail:       
Internet:     
ISIN:         DK0015966592
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------